Cat. No.: X23-10-ZQ469
Aurora kinase inhibitor GSK1070916, Purity ≥98%
Synonym: GSK1070916; 942918-07-2; GSK-1070916; GSK-1070916A; GSK 1070916; 3-(4-(4-(2-(3-((Dimethylamino)methyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl)phenyl)-1,1-dimethylurea; Aurora kinase inhibitor
- MDL: MFCD22420815
- CAS Number: 942918-07-2
- Compound CID: 46885626
Product Size
5 mg; 10 mg; 25 mg; 50 mg; 100 mg
Properties
Description
GSK1070916, soluble in DMSO and ethanol and insoluble in water, is an Aurora kinase inhibitor that disrupts cell division processes. It targets AuroraC-INCENP, FLT1, Aurora A-TPX2, AuroraB-INCENP, FGFR1, FLT4, SIK, and Tie-2.
Molecular Formula
C30H33N7O
Targets
AuroraC-INCENP: 6.5 nM; FLT1: 42 nM; Aurora A-TPX2: 1.1 nM; AuroraB-INCENP: 3.5 nM; FGFR1: 76 nM; FLT4: 74 nM; SIK: 70 nM; Tie-2: 59 nM
Solubility
DMSO: 91 mg/mL (179.26 mM); Water: Insoluble; Ethanol: 8 mg/mL (15.75 mM)
Identity
Confirmed by NMR/HPLC/MS.
Applications
GSK1070916 can be utilized to understand the therapeutic potential of Aurora B/C kinase inhibition in cancer models.
Related Products
Quick Links
